EP Patent

EP3865476A1 — Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia

Assigned to Alkermes Pharma Ireland Ltd · Expires 2021-08-18 · 5y expired

What this patent protects

Processes for providing depot injections of recrystallized aripiprazole lauroxil in which particles of the aripiprazole lauroxil have a surface area of about 0.50 to about 3.3 m<sup>2</sup>/g; and crystals of aripiprazole lauroxil produced by such processes.

USPTO Abstract

Processes for providing depot injections of recrystallized aripiprazole lauroxil in which particles of the aripiprazole lauroxil have a surface area of about 0.50 to about 3.3 m<sup>2</sup>/g; and crystals of aripiprazole lauroxil produced by such processes.

Drugs covered by this patent

Patent Metadata

Patent number
EP3865476A1
Jurisdiction
EP
Classification
—
Expires
2021-08-18
Drug substance claim
No
Drug product claim
No
Assignee
Alkermes Pharma Ireland Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.